This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.
Navidea Biopharmaceuticals (AMEX:NAVB) is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer. NAVB gets F’s in Equity and Cash Flow as well. For more information, get Portfolio Grader’s complete analysis of NAVB stock.
City Telecom (H.K.) Ltd. (NASDAQ:CTEL) provides fixed telecommunications networks and international telecommunications services for residential and corporate customers. CTEL also gets F’s in Earnings Growth and Operating Margin Growth. For more information, get Portfolio Grader’s complete analysis of CTEL stock.
HKTV gets F’s in Earnings Growth and Operating Margin Growth as well. For more information, get Portfolio Grader’s complete analysis of HKTV stock.
Immunomedics (NASDAQ:IMMU) develops, manufactures, and sells diagnostic imaging and therapeutic products. IMMU gets F’s in Earnings Growth, Equity, Cash Flow, and Operating Margin Growth as well. Shares of the stock have declined 16.7% since January 1. This is worse than the Nasdaq, which has seen a 1.6% increase over the same period. For more information, get Portfolio Grader’s complete analysis of IMMU stock.
Targacept (NASDAQ:TRGT) is an a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting neuronal nicotinic acetylcholine receptors. TRGT also gets an F in Analyst Earnings Revisions. The price of TRGT is down 4.3% since the first of the year. For more information, get Portfolio Grader’s complete analysis of TRGT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.